A Bay Street sign in Toronto’s financial district.© Mark Blinch / Reuters
IPO watch: Nearly a year after delaying plans to go public, the CEO of one of Canada's top private software firms, PointClickCare Technologies Inc., says there is "zero" chance his firm will do so in 2018 – but added that could rise to a "50-50" chance in the following two years. Story (Sean Silcoff, for subscribers)
Foreign expansion: Bank of Montreal is venturing deeper into China by expanding its relationship with the country's largest state-owned bank. Story (James Bradshaw)
Private equity: CPPIB paid $6-billion for luxury retailer Neiman Marcus. The bet backfired. Story (Tim Kiladze and Jacqueline Nelson, for subscribers)
ETFs: Mutual-fund giant Fidelity Investments is one step closer to launching its Canadian exchange-traded funds business after scooping up Raymond James fund expert Andrew Clee. Story (Clare O'Hara, for subscribers)
Value investor: When Fairfax Financial Holdings Ltd. inked its latest contrarian bet on a container-shipping business, it was motivated by more than just a turnaround story. Story (Jacqueline Nelson, for subscribers)
Pot takeovers: Executives with Aurora Cannabis Inc. and CanniMed Therapeutics Inc. have extended talks over what could be Canada's biggest marijuana-industry takeover deal following marathon negotiations through the weekend. Story (Christina Pelegrini and Jeff Jones, for subscribers)
Bank stocks: Canadian big bank stocks have continued to rise since the Bank of Canada raised its key interest rate on Wednesday, highlighting a nice safety feature for dividend-loving investors: Bank stocks can actually benefit from rising rates. Story (David Berman, for subscribers)
DEAL WRAP
Insurance deal: American International Group on Monday said it would buy reinsurer Validus Holdings for $5.56-billion (U.S.) in cash, snapping a long period of retrenchment for AIG as new Chief Executive Brian Duperreault plots an expansionist path. Story
Drug deal: Celgene Corp will pay $9-billion (U.S.) in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. Story
Health care deal: French health care group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6-billion (U.S.), its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. Story
Activist investor: Hedge fund managers Carl Icahn and Darwin Deason demanded on Monday that Xerox Corp explore strategic alternatives and said they would join forces to elect four new members to the board, prodding the company's shares higher. Story
Foreign IPO: Toshiba Corp is considering an IPO of its prized memory chip business if an agreed $18-billion (U.S.) (12.99 billion pounds) sale to a Bain Capital-led consortium fails to gain antitrust approval by the end of March, the Financial Times reported on Monday. Story
FINANCIAL SERVICES WRAP
Independents: Investors are betting Canada's smaller financial firms could see a jump in revenues after they helped fund marijuana companies ahead of the country's planned legalization of the drug this year. Story
Dividend increase: UBS is increasing payouts to shareholders as growing business with its core base of wealthy clients helps to offset the effects of tighter regulation and a one-off 2.9 billion Swiss franc ($3.76-billion) hit from U.S. tax reforms. Story
WHAT WE'RE READING ELSEWHERE
Private equity market: For Canada's private equity market, 2017 was the most active year in a decade. PE Hub
Innovation in research: When Chipotle Mexican Grill Inc.'s queso was trashed on Twitter after its debut last year, RBC Capital Markets assigned a machine to weigh the effect of the social media storm on the beleaguered burrito chain. Bloomberg
The Streetwise newsletter is daily. If you're reading this on the web, or if someone forwarded this e-mail to you, you can sign up for Streetwise and all Globe newsletters on our signup page.